Cargando…
A novel side effect of mitogen-activated protein kinase inhibitor cobimetinib: Acute corneal decompensation
A 38-year-old man with a diagnosis of BRAF-mutated metastatic melanoma was referred to our clinic. He had been under treatment with 60-mg oral cobimetinib daily for 21 days/7 day off in combination with 960 mg vemurafenib twice daily. The patient had symptoms of blurred vision and photophobia in his...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896530/ https://www.ncbi.nlm.nih.gov/pubmed/31755464 http://dx.doi.org/10.4103/ijo.IJO_2025_18 |